Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
FinancialNewsMedia.com News Commentary
PALM BEACH, FL, Oct. 17, 2023 /PRNewswire/ — Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US multiple myeloma therapeutics market is a growing market due to the increasing prevalence of multiple myeloma and the development of new therapies. The growth of the market is driven by factors such as an aging population, increasing prevalence of multiple myeloma, and advancements in the development of new therapies. The introduction of new therapies such as immunomodulatory drugs (IMiDs) and proteasome inhibitors has revolutionized the treatment of multiple myeloma. A report from Insights10 projected that the U.S. Multiple Myeloma Therapeutics Market was valued at $3.5 Billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 and will reach $4.26 Billion in 2030. Active companies in the markets this week include: Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO), Guardant Health, Inc. (NASDAQ: GH), Natera, Inc. (NASDAQ: NTRA), Quest Diagnostics Incorporated (NYSE: DGX), NeoGenomics, Inc. (NASDAQ: NEO).
Related news for (TDSGF)
- Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma
- Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)
- European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
- Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
- Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors